Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Yingjie
Contact Yingjie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Author Correction: Cancer SLC43A2 alters T cell methionine metabolism and histone methylation - Nature
Correction to: Nature https://doi.org/10.1038/s41586-020-2682-1 Published online 3 September 2020 In the version of the article initially published, due to a figure preparation mistake, in Extended Data Fig. 1j, the representative flow cytometry dot plot for condition “Sup+Ser” was mistakenly a duplicate image of condition “A375 sup.” The figure has been updated in the HTML and PDF versions of the article. About this article Bian, Y., Li, W., Kremer, D.M. et al.
Cancer SLC43A2 alters T cell methionine metabolism and histone methylation
Abstract Abnormal epigenetic patterns correlate with effector T cell malfunction in tumours1,2,3,4, but the cause of this link is unknown. Here we show that tumour cells disrupt methionine metabolism in CD8+ T cells, thereby lowering intracellular levels of methionine and the methyl donor S-adenosylmethionine (SAM) and resulting in loss of dimethylation at lysine 79 of histone H3 (H3K79me2). Loss of H3K79me2 led to low expression of STAT5 and impaired T cell immunity.
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Correction to: Nature Communications https://doi.org/10.1038/s41467-019-11782-w, published online 28 August 2019. The original version of this Article contained an error in the Results section, which incorrectly read ‘Erb-sumIL2 did not make any change for tumor control when used after afatinib treatment.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Yingjie
Contact Yingjie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack